Last reviewed · How we verify

NCT04184193

Benefits of Pulmonary Rehabilitation in Patients With Severe Lymphangioleiomyomatosis (LAM)

Completed Last updated 21 January 2020
What this trial tests

trial testing Pulmonary Rehabilitation in Lymphangioleiomyomatosis in 58 participants. Completed in 23 December 2019.

Timeline
3 December 2019
Primary endpoint
23 December 2019
23 December 2019

Quick facts

Lead sponsorSchön Klinik Berchtesgadener Land
StatusCompleted
Study typeOBSERVATIONAL
Enrollment58
Start date3 December 2019
Primary completion23 December 2019
Estimated completion23 December 2019
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Schön Klinik Berchtesgadener Land

Who can join

18 and older, any sex, with Lymphangioleiomyomatosis or LAM. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Data from patients with the orphan disease of lymphangioleiomyomatosis (LAM) which performed a pulmonary Rehabilitation program will be analyzed retrospectively. Data will be taken from the internal data base of the reference Center (Schoen Klinik Berchtesgadener Land, Schoenau, Germany) where These data were collected during clinical routine. Data will be included from the year 2000 until now. A retrospectively matched COPD cohort will be included for comparison.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Benefits of pulmonary rehabilitation in patients with advanced lymphangioleiomyomatosis (LAM) compared with COPD - a retrospective analysis.
    Gloeckl R, Nell C, Schneeberger T, Jarosch I, et al · · 2020 · cited 10× · PMID 32962746 · DOI 10.1186/s13023-020-01540-3

Verify or expand the search:

Other trials of Pulmonary Rehabilitation

Trials testing the same drug.

Other recruiting trials for Lymphangioleiomyomatosis

Currently open trials in the same condition.

Other Schön Klinik Berchtesgadener Land trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04184193.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing